A Phase 1 interventional study of ACT-541468 (hydrochloride salt) and ACT-541468 (free base) in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-10.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.
Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 12th largest by enrollment, is the only one that started in 2015, is the only one in phase 1, and was the 1st registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 730 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 40–62 · Women only
University Hospital, Montpellier · Sites in France
Ages 60–85
Sterling McPherson · Sites in United States
Ages 18+
Xuanwu Hospital, Beijing · Sites in China
Ages 18–70
Institut d'Investigació Biomèdica de Bellvitge · Sites in Spain
Ages 18–99
By country, each count listing its studies:
daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 389 Sleep Initiation and Maintenance Disorders studies recruiting now, 152 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 108 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2015.
This study's enrollment of 85 is above the median of 68 across 2,355 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 165 across the 16 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 9 most frequent:
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd.: none open now, 1 under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd., this one is the only one that started in 2015, is the only one in phase 1, and was the 1st registered.
Idorsia Pharmaceuticals Ltd.’s Sleep Initiation and Maintenance Disorders studies by the year they started, since 2015.
3 of the studies testing daridorexant in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07328594Legacy Health SystemImpact of Daridorexant on Sleep, Daytime Alertness, and Smoking | 2027-03-31 |
| NCT07555743Institut d'Investigació Biomèdica de BellvitgeEfficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia | 2027-04 |
| NCT05924425University Hospital, MontpellierDaridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease | 2027-05-13 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Idorsia Pharmaceuticals Ltd.’s 11 in Sleep Initiation and Maintenance Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK, or amount of drug over time in the body) and pharmacodynamics (PD, or effects on the body) of ACT-541468 following multiple ascending doses in healthy adults and following single ascending doses in healthy elderly subjects when administered in the morning. The safety, PK and PD of ACT-541468 will also be assessed after repeated evening administration of a selected dose in both healthy adults and elderly.
In the first-in-man study, single doses of ACT-541468 administered in healthy young adults were well tolerated up to the dose level of 200 mg (inclusive) and yielded results compatible with possible sleep facilitating effects of ACT-541468. So the present study aimed to further investigate the effects of ACT-541468 after multiple ascending doses in healthy young subjects as well as after single ascending doses in elderly subjects (morning administrations). The effects of repeated administrations of a selected dose administered in the evening in both healthy adults and elderly, will also be investigated.
Inclusion Criteria:
Exclusion Criteria:
Principal exclusion criteria common to young adults and elderly:
Exclusion criteria for young adults only:
Exclusion criteria for elderly only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Six young adults will receive ACT-541468 in the morning from Day 1 to Day 5 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 10, 25 and 75 mg per day
Drug: ACT-541468 (hydrochloride salt)
For each ACT-541468 dose level tested in Part A, 2 young adults will receive matching placebo in the same conditions (total number of subjects = 6)
Drug: Placebo
Six elderly will receive ACT-541468 in the morning of Day 1 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 5, 15 and 25 mg
Drug: ACT-541468 (hydrochloride salt)
For each ACT-541468 dose level tested in Part B, 2 elderly will receive matching placebo in the same conditions (total number of subjects = 6)
Drug: Placebo
Sixteen young adults and eight elderly will receive ACT-541468 (planned dose: 25 mg) in the evening for 7 days (8 days for 6 of the 16 young adults).
Drug: ACT-541468 (free base)
Four young adults and 2 elderly will receive matching placebo in the same conditions as subjects receiving the active compound in Part C
Drug: Placebo
Hard-gelatin capsules (strength: 5 mg and 25 mg)
Soft capsules (strength: 25 mg)
Placebo capsules matching the ACT-541468 formulations
Number of participants with Adverse Events (AEs)
Treatment emergent adverse events and treatment emergent serious adverse events will be evaluated throughout the study
Time frame: up to 72 hours post dosing
Changes from baseline in ECG variables and vital signs (heart rate and blood pressure)
12-lead electrocardiogram variables including RR, PR, QRS, QT and QTc intervals at scheduled time points during Parts A, B and C
Time frame: up to 72 hours post dosing
Changes from baseline in clinical laboratory parameters
Laboratory tests including hematology, blood chemistry and urinalysis at scheduled time points during PArts A, B and C
Time frame: up to 72 hours post dosing
Maximum plasma concentration (Cmax) of ACT-541468 after daytime and bedtime intake
Cmax will be determined after single (Parts A and B) and multiple morning doses (Part A) as well as after repeated evening doses to identify the nighttime PK profile (Part C)
Time frame: Part A: Day 1 and Day 5; Part B: Day 1; Part C: evening of Day 8 (pre-dose) and Day 9 (nighttime samples)
Time to reach Cmax (tmax) of ACT-541468 after daytime and bedtime intake
tmax will be determined after single (Parts A and B) and multiple morning doses (Part A) as well as after repeated evening doses to identify the nighttime PK profile (Part C)
Time frame: Part A: Day 1 and Day 5; Part B: Day 1; Part C: evening of Day 8 (pre-dose) and Day 9 (nighttime samples)
Terminal half-life [t(1/2)] after daytime and bedtime intake
t(1/2) will be determined after single (Parts A and B) and multiple morning doses (Part A) as well as after repeated evening doses (Part C)
Time frame: Part A: Days 1 and 5, from pre-dose up to 72 h post-dose; Part B: Day 1, at pre-dose up to 72 h post-dose; Part C: from the morning of Day 8 up to 60 h post-dose and from the evening of Day 8 (pre-dose) until 36 h post-dose (with nighttime samples)
Areas under the plasma concentration-time curves [AUC(0-8), AUC(0-24)] of ACT-541468 after daytime and bedtime intake
AUC from time 0 to 8 hours after study drug administration \[AUC(0--8)\] and from time 0 to 24 hours after study drug administration \[AUC(0--24)\] will be determined after single (parts A and B) and multiple morning doses (Part A) as well as after multiple evening doses (Part C)
Time frame: Part A: Days 1 and 5, from pre-dose up to 72 h post-dose; Part B: Day 1, at pre-dose up to 72 h post-dose; Part C: from the morning of Day 8 up to 60 h post-dose and from the evening of Day 8 (pre-dose) until 36 h post-dose (with nighttime samples)
Areas under the plasma concentration-time curves [AUC(0-t), AUC(0-inf)] of ACT-541468 after daytime and bedtime intake
AUC from time 0 to infinity \[AUC(0--inf\], AUC from time 0 to time of the last measured concentration above the limit of quantification \[AUC(0--t)\] will be determined after single (Part B) and multiple morning doses (Part A) as well as after multiple evening doses (Part C)
Time frame: Part A: Day 5, from pre-dose up to 72 h post-dose; Part B: Day 1, at pre-dose up to 72 h post-dose; Part C: from the morning of Day 8 up to 60 h post-dose and from the evening of Day 8 (pre-dose) until 36 h post-dose (with nighttime samples)
Sedation as measured by saccadic peak velocity
saccadic eye movements (SEM) will be recorded by electrooculography and the average values of saccadic peak velocity of the SEM will be used as parameter of sedation
Time frame: Part A: Day 1 and Day 5; Part B: Day 1; Part C: Day 2 and Day 14
Visual motor coordination
Visual motor coordination will be assessed with the adaptive tracking test and the average tracking performance will be used as parameter of coordination
Time frame: Part A: Day 1 and Day 5; Part B: Day 1; Part C: Day 2 and Day 14
Change from baseline in body sway
Body sway will be assessed using a body sway meter
Time frame: Part A: Day 1 and Day 5; Part B: Day 1; Part C: Day 2 and Day 14
Change from baseline in subjective cognitive effects
Subjects will rate sleepiness, alertness and mood using questionnaires
Time frame: Part A: every day from Day 1 to Day 6; Part B: Day 1; Part C: Day 1 to Day 8
Ran from Oct 2015 to primary completion in Feb 2016, 4 months.
Of 23 industry-sponsored phase 1 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 4 months of starting (the median); a quarter within 1 and three quarters within 5. This study's 4 months is close to that.
Counting every sponsor, half of 39 studies reached it within 5 months; a quarter within 3 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daridorexant
Sleep Initiation and Maintenance Disorders →
Idorsia Pharmaceuticals Ltd. →